Loading quotes...

Forecast

The analysts' average price target is €571.22 (-4.41%). The median is €583.81 (-2.31%).

Buy	4
Hold	15
Sell	0

News Go to news feed

Medpace positions itself for AI revolution in the healthcare sector

The healthcare sector is seen as the next big market for AI, with Medpace and Thermo Fisher named as holdings in a US model portfolio. The biotech sector in particular stands to benefit, as AI identifies drug candidates more quickly, predicts protein structures, and makes therapies more targeted. This could turn early drug research from lengthy testing into a data-driven selection process. » More on finanzen.net
Medpace benefits from AI potential in biotech after strong second quarter

Medpace, a global contract research organization and full-service partner for clinical trials, reported an outstanding second quarter. The company provides study design, clinical monitoring, biostatistical analysis and integrated lab services and focuses on small and mid-sized biotech firms. Medpace is seen as a potential winner from AI adoption in biotechnology, as rising numbers of clinical trials could accelerate demand growth for its services. » More on finanzen.net
Medpace: revenue rises 17.2% in Q2, net order intake climbs 28.2% and full-year guidance up to $2.89 billion

Medpace reports revenue of $707.3 million (+17.2%) for the second quarter of 2026 and a 28.2% increase in net order intake, improving the predictability of its business base. The company confirms full-year guidance of up to $2.89 billion for 2026. The news triggered a roughly 16% jump in the share price, pushing the stock toward its all-time high. » More on finanzen.net

Financials

In the last quarter, Medpace had revenue of €632.12m and net profit of €121.36m

(EUR)	September 2026	YoY
Revenue	632.12m	12.41%
Gross profit	197.66m	17.78%
Net profit	121.36m	28.15%
EBITDA	156.69m	22.68%

Fundamentals

Metric	Value
Market capitalization	€16.71bn
Number of shares	27.97m
52-week high/low	€611.05 - €332.97
Dividends	No
Beta	1.18
P/E ratio	36.45
PEG ratio	1.44
P/B ratio	31.96
P/S ratio	6.59

Company profile

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.